FDA Approval Triggers $50M Milestone for Protagonist
Protagonist Therapeutics (NASDAQ: PTGX) will receive a $50 million milestone payment from its partner Johnson & Johnson following the U.S. Food and Drug Administration's (FDA) approval of ICOTYDE (icotrokinra). The once-daily oral peptide is approved for treating moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older. Johnson & Johnson will manage the drug's commercial launch and global marketing.
The approval initiates a significant revenue stream for Protagonist beyond the initial payment. The agreement entitles the company to tiered royalties ranging from 6% to 10% on global net sales. This builds on the $387 million in collaboration payments Protagonist has already received from Johnson & Johnson since 2017, with approximately $580 million in potential future milestones remaining. The drug's commercial potential is secured by patent protection extending to 2040.
ICOTYDE Shows Superiority with 70% Skin Clearance in Trials
The FDA's decision was supported by a robust Phase 3 program involving approximately 2,500 patients across four studies. In head-to-head superiority trials against an active comparator, ICOTYDE demonstrated strong efficacy. Approximately 70% of patients treated with ICOTYDE achieved clear or almost clear skin at week 16, and 55% achieved a Psoriasis Area and Severity Index (PASI) 90 response.
The drug also showed a favorable safety profile through 52 weeks of study, with no new safety signals identified. As the first targeted oral peptide that blocks the IL-23 receptor, ICOTYDE offers a convenient alternative to injectable therapies, positioning it to capture a significant share of the psoriasis treatment market, which affects over 8 million people in the U.S.
Focus Shifts to Q3 Rusfertide Decision
With ICOTYDE's approval secured, investor attention turns to Protagonist's next major catalyst: an FDA decision on its drug rusfertide, expected in the third quarter of the year. Rusfertide is a first-in-class treatment for the rare blood disorder polycythemia vera and is being developed in partnership with Takeda.
Protagonist's management indicated it is strongly considering opting out of its co-development and co-commercialization agreement with Takeda for rusfertide. Such a move would trigger a $400 million payment to Protagonist and convert the partnership into a more traditional licensing deal with enhanced milestones and royalties. This potential influx of non-dilutive capital has prompted the company to consider shareholder return initiatives, including share buybacks, later in the year.
